Please assess the completion status of the following clinical trial:

Trial Title: Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (18 years or older) of any race and either sex, requiring cataract extraction with planned implantation of a posterior chamber intraocular lens.~* Other protocol-defined inclusion criteria may apply.~Exclusion Criteria:~* Under 18.~* Other protocol-defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nepafenac (Type: EXPERIMENTAL): One drop in the study eye 3 times daily for 23 days
- Ketorolac Trometamol (Type: ACTIVE_COMPARATOR): One drop in the study eye 3 times daily for 23 days
- Nepafenac Vehicle (Type: PLACEBO_COMPARATOR): One drop in the study eye 3 times daily for 23 days

Based on this trial design, predict the completion outcome and termination type (if applicable).